Legal Dispute
Gujarat Themis Biosyn Initiates Arbitration Against Optimus Drugs Over Supply Agreement Dispute
NSE
GUJTHEM
BSE
506879
Gujarat Themis Biosyn Limited has initiated arbitration proceedings against Optimus Drugs Private Limited, alleging breach of a supply agreement and claiming compensation, interest, damages, and other reliefs. The company stated that it does not expect any adverse financial implication from the litigation.
PRICE-SENSITIVE TRIGGER
Event: Initiation of arbitration proceedings against Optimus Drugs Private Limited.
Type: Legal Dispute
Impact: Neutral
Immediate Effect: The company has formally commenced arbitration proceedings before a Sole Arbitrator to recover contractual dues, damages, and related claims arising from the alleged breach of a supply agreement.
Key Metrics:
- Primary Claim (Break Fees): ₹75.00 crore
- Interest on Delayed Payments: ₹23.81 lakh
- Damages & Financial Losses Claimed: ₹15.00 crore
- Additional Relief: Costs and other reliefs as determined by the Arbitration Tribunal
Highlight:
- The arbitration claim exceeds ₹90 crore (excluding future interest, litigation costs, and any additional relief awarded by the tribunal).
What Happened ?
Gujarat Themis Biosyn Limited informed the stock exchanges that it has initiated arbitration proceedings against Optimus Drugs Private Limited following the alleged termination of a supply agreement in violation of the agreed contractual terms.
According to the company, Optimus Drugs allegedly breached the mandatory “Take-or-Pay” minimum purchase obligations under the agreement. Gujarat Themis Biosyn is seeking recovery of contractual break fees, interest on delayed payments, damages for financial losses, litigation costs, and other reliefs before the Learned Sole Arbitrator.
The company clarified that, since it is the claimant seeking compensation, it does not expect any financial liability arising from the proceedings.
Key Details
Arbitration Proceedings:
- Gujarat Themis Biosyn Limited has initiated arbitration against Optimus Drugs Private Limited.
- The proceedings are being conducted before the Learned Sole Arbitrator.
- The dispute relates to the alleged wrongful termination of a supply agreement.
- The company alleges that Optimus Drugs breached the mandatory “Take-or-Pay” minimum purchase obligations.
- Claims filed include:
- ₹75.00 crore towards contractual break fees.
- ₹23.81 lakh towards interest on delayed payments, along with further interest until payment.
- ₹15.00 crore towards damages and financial losses.
- Litigation costs and any additional relief deemed appropriate by the arbitral tribunal.
Note:
- Gujarat Themis Biosyn stated that it does not anticipate any adverse financial implication from the arbitration since it is pursuing recovery of damages rather than facing a liability claim.
Risk Analysis
Summary:
- The disclosure represents the commencement of legal proceedings rather than the resolution of the dispute. The eventual financial outcome will depend on the arbitral award and the enforceability of any judgment.
Key Points:
- Arbitration proceedings may extend over a prolonged period.
- Recovery of claimed amounts is subject to the final arbitral decision.
- The company currently expects no financial outflow from this litigation.
- Legal costs and timelines remain dependent on the arbitration process.
Worst Case:
- If the arbitration does not result in a favorable award or recovery of claimed amounts, the company may not realize the expected compensation and could incur litigation-related expenses.
Risk Level: Medium
Company Commentary
- Optimus Drugs allegedly terminated the supply agreement contrary to agreed contractual terms.
- Gujarat Themis Biosyn has initiated arbitration to recover contractual dues and damages.
- The company is seeking break fees, interest, damages, litigation costs, and other appropriate relief.
- Since the company is the claimant, it does not expect any financial implication arising from penalties or compensation.
Official Exchange Filing: Gujarat Themis Biosyn Limited
